Table 2 Difference analysis of variables in training cohort
| Â | ICI-P | Non ICI-P | P value |
|---|---|---|---|
Age | |||
 < 60 | 15/20 (75.00%) | 162/225 (72.00%) | 0.77 |
 ≥ 60 | 5/20 (25.00%) | 63/225 (28.00%) | |
Gender | |||
 Male | 9/20 (45.00%) | 102/225 (45.33%) | 0.98 |
 Female | 11/20 (55.00%) | 123/225 (54.67%) | |
BMI | |||
 < 25 | 1/20 (5.00%) | 26/225 (11.56%) | 0.37 |
 ≥ 25 | 19/20 (95.00%) | 199/225 (88.44%) | |
Smoking history | |||
 Yes | 13/20 (65.00%) | 33/225 (14.67%) | < 0.01 |
 No | 7/20 (35.00%) | 192/225(85.33%) | |
Lung cancer | |||
 Yes | 4/20 (20.00%) | 62/225 (27.56%) | 0.47 |
 No | 16/20 (80.00%) | 163/225 (72.44%) | |
Lung metastasis | |||
 Yes | 7/20 (35.00%) | 64/225 (28.44%) | 0.54 |
 No | 13/20 (65.00%) | 161/225 (71.56%) | |
Pleural effusion | |||
 Yes | 8/20 (40.00%) | 36/225 (16%) | < 0.01 |
 No | 12/20 (60.00%) | 189/225 (84%) | |
PD-1/PD-L1 | |||
 PD-1 | 11/20 (55.00%) | 98/225 (43.56%) | 0.32 |
Antibody | |||
 PD-L1 | 9/20 (45.00%) | 127/225 (56.44%) | |
EGFR antibody | |||
 Yes | 1/20 (5.00%) | 31/225 (13.78%) | 0.26 |
 No | 19/20 (95.00%) | 194/225 (86.22%) | |
Gemcitabine | |||
 Yes | 2/20 (10.00%) | 24/225 (10.67%) | 0.77 |
 No | 18/20 (90.00%) | 201/225 (89.33%) | |
Lung surgery | |||
 Yes | 1/20 (5.00%) | 31/225 (13.78%) | 0.26 |
 No | 19/20 (95.00%) | 194/225 (86.22%) | |
Chest radiotherapy | |||
 Yes | 0/20 (0.00%) | 21/225 (9.33%) | 0.31 |
 No | 20/20 (100.00%) | 204/225 (90.67%) | |
Therapy line | |||
 Non 1st | 12/20 (60.00%) | 39/225 (17.33%) | < 0.01 |
 1st | 8/20 (40.00%) | 186/225 (82.67%) | |
Squamous cancer | |||
 Yes | 11/20 (55.00%) | 91/225 (40.44%) | 0.27 |
 No | 9/20 (45.00%) | 124/225 (59.56%) | |
COPD | |||
 Yes | 4/20 (20.00%) | 27/225 (12%) | 0.51 |
 No | 16/20 (80.00%) | 198/225 (88%) | |
Asthma | |||
 Yes | 2/20 (10.00%) | 21/225 (9.33%) | 0.76 |
 No | 18/20 (90.00%) | 204/225 (90.67%) | |
IL-6 (pg/ml) | 55.12 (45.13–65.11) | 39.32 (36.27–42.37) | < 0.01 |
CRP (mg/L) | 101.07 (77.36–124.79) | 80.1 (74.94–85.25) | 0.03 |
CD3 + T (/ul) | 1863.65 (1676.71–2050.59) | 1924.29 (1871.97–1976.62) | 0.51 |
CD4 + T (/ul) | 884.45 (718.67–1050.23) | 879.91 (826.48–933.34) | 0.96 |
CD8 + T (/ul) | 825.85 (616.79–1034.91) | 651.44 (598.89–703.98) | 0.07 |
SP-A (ng/ml) | 67.71 (60.64–74.78) | 61.44 (60.03–62.85) | 0.06 |
SP-D (ng/ml) | 67.71 (60.64–74.78) | 257.8 (253.45–262.14) | 0.02 |
KL-6 (U/ml) | 460.3 (408.44–512.16) | 398.16 (381.49–414.83) |  < 0.01 |
FVC (%) | 67.52 (64.23–70.82) | 68.56 (67.64–69.48) | 0.52 |
Total | 20 | 225 | Â |